Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”),…
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up…
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Investor webcast to be held on Monday November 3, 2025 at 8:00…
